Physician profile
Christine Bender
NPI 1891780847
$1,849.56
in general payments reported to CMS, 2019-2025
23 companies · $296 in 2025
The $296 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $143 · 2021: $208 · 2022: $280 · 2023: $416 · 2024: $277 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $232.45 | 2020-2024 | Nucala, Pediarix, Bexsero |
| Corium, LLC | $194.76 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $187.67 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $162.21 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $153.57 | 2019-2025 | |
| Cranial Technologies, INC | $136.75 | 2020-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $130.96 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $128.04 | 2021-2025 | Qelbree |
| Adlon Therapeutics L.P. | $88.94 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $78.41 | 2021-2024 | Crysvita |
| Shire North American Group INC | $53.33 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $47.25 | 2025 | Neffy |
| Tris Pharma INC | $44.64 | 2019-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $38.07 | 2024-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Rhodes Pharmaceuticals L.P. | $36.53 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $31.39 | 2023-2025 | Xelstrym |
| Sanofi Pasteur INC. | $22.41 | 2024 | |
| Lnhc, INC | $16.51 | 2025 | Zelsuvmi |
| Ironwood Pharmaceuticals, INC | $15.77 | 2024 | |
| Sobi, INC | $14.60 | 2019 | |
| Medline Industries LP | $14.17 | 2023 | Medline Industries, INC., Remedy Antifungal |
| Kaleo, INC. | $12.90 | 2019 | |
| Romark Laboratories, Lc | $8.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.